Back to Search Start Over

Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the safety and efficacy large-scale evaluation of COX-inhibiting therapies (Select) trial in osteoarthritis

Authors :
Dequeker, J
Hawkey, C
Kahan, A
Steinbrück, K
Alegre, C
Baumelou, E
Bégaud, B
Isomäki, H
Littlejohn, G
Papazoglou, S
Source :
Rheumatology; September 1998, Vol. 37 Issue: 9 p946-951, 6p
Publication Year :
1998

Abstract

S&ELECT is a large-scale, prospective, international, multicentre, double-blind, double-dummy, randomized, parallel-group trial. Patients with exacerbation of osteoarthritis were treated with the recommended dose of meloxicam (7.5 mg) or piroxicam (20 mg) once daily for 28 days; 4320 patients were administered meloxicam and 4336 piroxicam. The incidence of adverse events was significantly lower in the meloxicam group (22.5%) compared with the piroxicam group (27.9%; P<0.001), mainly due to the significantly lower incidence of gastrointestinal (GI) adverse events in the meloxicam than in the piroxicam group (10.3% vs 15.4%; P<0.001), while the efficacy of both drugs was equivalent. Individual GI events occurred significantly less often with meloxicam than piroxicam: dyspepsia (3.4% vs 5.8%; P<0.001), nausea/vomiting (2.5% vs 3.4%; P<0.05) and abdominal pain (2.1% vs 3.6; P<0.001). There were 16 patients with perforations, ulcerations or bleeding (PUBs) of the upper GI tract in the piroxicam group compared with seven in the meloxicam group (relative risk piroxicam:meloxicam = 1.4). Four PUBs were complicated (perforations or bleedings); none of these occurred in the meloxicam group (relative risk piroxicam:meloxicam = 1.9). the outcome of SELECT is consistent with that of the large-scale clinical trial of similar design and size which compared 7.5 mg meloxicam with 100 mg diclofenac in patients with osteoarthritis, and with a previous global analysis of the safety of meloxicam. It adds further data to the proposed relationship between selective inhibition of cyclooxygenase-2 and improved GI tolerability of non-steroidal anti-inflammatory drugs.Keywords:Meloxicam, Piroxicam, Osteoarthritis, Gastrointestinal tolerability, Cyclooxygenase, Perforations, ulcerations or bleedings

Details

Language :
English
ISSN :
14620324 and 14620332
Volume :
37
Issue :
9
Database :
Supplemental Index
Journal :
Rheumatology
Publication Type :
Periodical
Accession number :
ejs7686466